Proteomic profiling of human respiratory epithelia by iTRAQ reveals biomarkers of exposure and harm by tobacco smoke components

Biomarkers

Volumn 16, Issue 7, 2011, Pages 567-576

  Sexton, Keith ^a   Balharry, Dominique ^a   Brennan, Paul ^b   McLaren, James ^a   Brewis, Ian A ^b   Bérubé, Kelly A ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; isobaric labeling; lung; tandem mass spectrometry; tobacco smoke

Indexed keywords

ADENOSINE TRIPHOSPHATE DEPENDENT DNA HELICASE 2 SUBUNIT 2; ALDOKETOREDUCTASE FAMILY 1 MEMBER C1; BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; CALMODULIN; CD9 ANTIGEN; COMPLEMENT COMPONENT C3; CORNIFIN B; CYTOCHROME B; CYTOCHROME B D COMPLEX SUBUNIT 7; CYTOCHROME C OXIDASE 7C; CYTOCHROME D; DIPEPTIDYL PEPTIDASE I; FILAMIN A; HISTONE H1.2; MYB RELATED PROTEIN A; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROTEIN PLUNC; PUTATIVE TROPOMYOSIN ALPHA 3 CHAIN LIKE PROTEIN; RIBONUCLEOPROTEIN; STEFIN A; TOBACCO SMOKE; UBIQUITIN; UNCLASSIFIED DRUG;

ANALYTIC METHOD; ARTICLE; CYTOLYSIS; EXPOSURE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPERPLASIA; HYPERTROPHY; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; LUNG INJURY; NECROSIS; PROTEOMICS; RESPIRATORY EPITHELIUM; SMOKING; VAPOR;

BIOLOGICAL MARKERS; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORESIS, POLYACRYLAMIDE GEL; GENE EXPRESSION PROFILING; HUMANS; PROTEOME; PROTEOMICS; RESPIRATORY MUCOSA; SMOKING; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

NICOTIANA TABACUM;

EID: 80054922720     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2011.608855     Document Type: Article

References (37)

1. Balharry D, Sexton K, BéruBé KA. (2008). An in vitro approach to assess the toxicity of inhaled tobacco smoke components: nicotine, cadmium, formaldehyde and urethane. Toxicology 244:66-76. (Pubitemid 50015302)
2. Benowitz NL. (2003). Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Prog Cardiovasc Dis 46:91-111.
3. Bérubé K, Prytherch Z, Job C, Hughes T. (2010). Human primary bronchial lung cell constructs: the new respiratory models. Toxicology 278:311-318.
4. BéruBé K, Aufderheide M, Breheny D, Clothier R, Combes R, Duffin R, Forbes B, Gaça M, Gray A, Hall I, Kelly M, Lethem M, Liebsch M, Merolla L, Morin JP, Seagrave J, Swartz MA, Tetley TD, Umachandran M. (2009). In vitro models of inhalation toxicity and disease. The report of a FRAME workshop. Altern Lab Anim 37:89-141.
5. Bérubé KA, Balharry D, Jones TP, Moreno T, Hayden P, Sexton K, Hicks M, Merolla L, Timblin C, Shukla A, Mossman BT. (2006). Characterisation of airborne particulate matter and related mechanisms of toxicity: an experimental approach. In: J., Ayres, R., Maynard & Richards, R (eds.) Air Pollution Reviews. London: Imperial College Press.
6. Bradford MM. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Brennan P, Shore AM, Clement M, Hewamana S, Jones CM, Giles P, Fegan C, Pepper C, Brewis IA. (2009). Quantitative nuclear proteomics reveals new phenotypes altered in lymphoblastoid cells. Proteomics Clin Appl 3:359-369.
8. Caminati A, Graziano P, Sverzellati N, Harari S. (2010). Smoking-related interstitial lung diseases. Pathologica 102:525-536.
9. Confalonieri S, Quarto M, Goisis G, Nuciforo P, Donzelli M, Jodice G, Pelosi G, Viale G, Pece S, Di Fiore PP. (2009). Alterations of ubiquitin ligases in human cancer and their association with the natural history of the tumor. Oncogene 28:2959-2968.
10. Funakoshi T, Tachibana I, Hoshida Y, Kimura H, Takeda Y, Kijima T, Nishino K, Goto H, Yoneda T, Kumagai T, Osaki T, Hayashi S, Aozasa K, Kawase I. (2003). Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cell motility in small cell lung cancer. Oncogene 22:674-687. (Pubitemid 36269281)
11. Gamble W. (2006). Atherosclerosis: the carbonic anhydrase, carbon dioxide, calcium concerted theory. J Theor Biol 239:16-21.
12. Glauert A, Lewis P. (1998). Biological specimen preparation for transmission electron microscopy. Chapter 5. Embedding methods. In: Glauert, A (ed.) Practical Methods in Electron Microscopy.
13. Glückmann M, Fella K, Waidelich D, Merkel D, Kruft V, Kramer PJ, Walter Y, Hellmann J, Karas M, Kröger M. (2007). Prevalidation of potential protein biomarkers in toxicology using iTRAQ reagent technology. Proteomics 7:1564-1574.
14. Gowadia N, Oldham MJ, Dunn-Rankin D. (2009). Particle size distribution of nicotine in mainstream smoke from 2R4F, Marlboro Medium, and Quest1 cigarettes under different puffing regimens. Inhal Toxicol 21:435-446.
15. Green CR, Rodgman A. (1996). The tobacco chemists' research conference; A half century of advances in analytical methodology of tobacco and its products. Recent Adv Tob Sci 22:131-304.
16. Gygi SP, Aebersold R. (2000). Mass spectrometry and proteomics. Curr Opin Chem Biol 4:489-494.
17. Higashiyama M, Taki T, Ieki Y, Adachi M, Huang CL, Koh T, Kodama K, Doi O, Miyake M. (1995). Reduced motility related protein-1 (MRP-1/CD9) gene expression as a factor of poor prognosis in non-small cell lung cancer. Cancer Res 55:6040-6044.
18. Hoffmann D, Hoffmann I, El-Bayoumy K. (2001). The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol 14:767-790. (Pubitemid 32663874)
19. Innes AL, Woodruff PG, Ferrando RE, Donnelly S, Dolganov GM, Lazarus SC, Fahy JV. (2006). Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction. Chest 130:1102-1108. (Pubitemid 44583741)
20. Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics, 2010. ca Cancer J Clin 60:277-300.
21. Jennings LK, Fox CF, Kouns WC, McKay CP, Ballou LR, Schultz HE. (1990). The activation of human platelets mediated by antihuman platelet p24/CD9 monoclonal antibodies. J Biol Chem 265:3815-3822.
22. Karp NA, Huber W, Sadowski PG, Charles PD, Hester SV, Lilley KS. (2010). Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics 9:1885-1897.
23. Keppler D. (2006). Towards novel anti-cancer strategies based on cystatin function. Cancer Lett 235:159-176.
24. Lancet. (2009). Tobacco smoking: why start? Lancet 374:1038.
25. Lee EJ, In KH, Kim JH, Lee SY, Shin C, Shim JJ, Kang KH, Yoo SH, Kim CH, Kim HK, Lee SH, Uhm CS. (2009). Proteomic analysis in lung tissue of smokers and COPD patients. Chest 135:344-352.
26. Lee J, Cooke JP. (2011). The role of nicotine in the pathogenesis of atherosclerosis. Atherosclerosis 215:281-283.
27. Leinonen T, Pirinen R, Böhm J, Johansson R, Rinne A, Weber E, Kosma VM. (2007). Biological and prognostic role of acid cysteine proteinase inhibitor (ACPI, cystatin A) in non-small-cell lung cancer. J Clin Pathol 60:515-519. (Pubitemid 46867161)
28. Matthay MA, Zimmerman GA, Esmon C, Bhattacharya J, Coller B, Doerschuk CM, Floros J, Gimbrone MA Jr, Hoffman E, Hubmayr RD, Leppert M, Matalon S, Munford R, Parsons P, Slutsky AS, Tracey KJ, Ward P, Gail DB, Harabin AL. (2003). Future research directions in acute lung injury: summary of a National Heart, Lung, and Blood Institute working group. Am J Respir Crit Care Med 167:1027-1035. (Pubitemid 36408170)
29. Miyake M, Nakano K, Itoi SI, Koh T, Taki T. (1996). Motility-related protein-1 (MRP-1/CD9) reduction as a factor of poor prognosis in breast cancer. Cancer Res 56:1244-1249. (Pubitemid 26080963)
30. Ouchi N, Kihara S, Yamashita S, Higashiyama S, Nakagawa T, Shimomura I, Funahashi T, Kameda-Takemura K, Kawata S, Taniguchi N, Matsuzawa Y. (1997). Role of membrane-anchored heparin-binding epidermal growth factor-like growth factor and CD9 on macrophages. Biochem J 328 (Pt 3):923-928. (Pubitemid 28005794)
31. Pradet-Balade B, Boulme F, Beug H, Mullner E, Garcia Sanz J. (2001). Cytokine balance translation control: bridging the gap between genomics and proteo- in the lungs of patients with acute respiratory distress syndrome. Trends Biochem Sci 26:225-229.
32. Roberts DL. (1988). Natural tobacco flavour. Adv Tob Sci 14:49-81.
33. Rousseau S, Morrice N, Peggie M, Campbell DG, Gaestel M, Cohen P. (2002). Inhibition of SAPK2a/p38 prevents hnRNP A0 phosphorylation by MAPKAP-K2 and its interaction with cytokine mRNAs. Embo J 21:6505-6514. (Pubitemid 35448428)
34. Sexton K, Balharry D, BéruBé KA. (2008). Genomic biomarkers of pulmonary exposure to tobacco smoke components. Pharmacogenet Genomics 18:853-860.
35. Steiling K, Kadar AY, Bergerat A, Flanigon J, Sridhar S, Shah V, Ahmad QR, Brody JS, Lenburg ME, Steffen M, Spira A. (2009). Comparison of proteomic and transcriptomic profiles in the bronchial airway epithelium of current and never smokers. Plos one 4:e5043.
36. Suzuki M, Tachibana I, Takeda Y, He P, Minami S, Iwasaki T, Kida H, Goya S, Kijima T, Yoshida M, Kumagai T, Osaki T, Kawase I. (2009). Tetraspanin CD9 negatively regulates lipopolysaccharide-induced macrophage activation and lung inflammation. J Immunol 182: 6485-6493.
37. Széplaki G, Prohászka Z, Duba J, Rugonfalvi-Kiss S, Karádi I, Kókai M, Kramer J, Füst G, Kleiber M, Romics L, Varga L. (2004). Association of high serum concentration of the third component of complement (C3) with pre-existing severe coronary artery disease and new vascular events in women. Atherosclerosis 177:383-389. (Pubitemid 39505272)